PANKAJ KUMAR SINGH to Protein Kinase Inhibitors
This is a "connection" page, showing publications PANKAJ KUMAR SINGH has written about Protein Kinase Inhibitors.
Connection Strength
0.092
-
Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC. Mol Divers. 2021 May; 25(2):1091-1102.
Score: 0.061
-
Development of asolectin-based liposomal formulation for controlled and targeted delivery of erlotinib as a model drug for EGFR monotherapy. J Liposome Res. 2022 Dec; 32(4):386-395.
Score: 0.018
-
YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer. Clin Cancer Res. 2019 04 01; 25(7):2264-2277.
Score: 0.014